A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

This is a single centre, single-dose, non-randomised, open label study. The primary objectives of this study are to assess the mass balance recovery and provide biosamples for metabolite profiling and structural identification after a single oral dose of [14C]-AK0529 in healthy male subjects. 7 subjects will be recruited to receive a single oral administration of a solution containing 300 mg AK0529. The total duration of the study will be approximately 6 weeks.

Inclusion criteria

• Healthy males
• Aged between 30 and 55 years of age, inclusive
• Body mass index of 18.0 to 35.0 kg/m2, inclusive, or, if outside the range, considered not clinically significant by the investigator and the medical monitor
• Must be willing and able to communicate and participate in the whole study
• Must have regular daily bowel movements
• Must provide written informed consent
• Must agree to use an adequate method of contraception

Exclusion criteria

• Subjects who have received any IMP in a clinical research study within the previous 3 months
• Subjects who are study site or sponsor employees, or immediate family members of a study site or sponsor employee
• Subjects who have previously been enrolled in this study
• History of any drug or alcohol abuse in the past 2 years
• Regular alcohol consumption >21 units per week
• Current smokers and those who have smoked within the last 12 months
• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
• Radiation exposure. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
• Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
• Abnormal liver function as assessed by clinical chemistry
• Positive drugs of abuse test result
• Positive HBsAg, HCV Ab or HIV results
• Evidence of renal impairment at screening
• History of clinically significant cardiovascular, renal, hepatic, chronic respiratory, neurological, dermatological or GI disease, or psychiatric disorder, as judged by the investigator
• Any abnormality of ECG parameters
• Any abnormality of cardiac rhythm or history thereof
• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
• Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed, unless it is active at screening or admission
• Donation or loss of greater than 400 mL of blood within the previous 3 months
• Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal or any other 'alternative' remedies in the 14 days before IMP administration
• Failure to satisfy the investigator of fitness to participate for any other reason